Talking Points

Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and multivessel CAD undergoing PCI.

C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.

Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.

Thomas Crawford meets with C. Michael Gibson to discuss the role of reconditioned pacemakers in low- and middle-income countries.

Mamas Mamas, Birgitte Krogsgaard Andersen, and Niels Ramsing Holm discuss QFR versus FFR for guiding resvascularization in patients with coronary stenoses.

C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.

James Benenati, Robert Lookstein, and Rachel Rosovsky discuss the STORM-PE trial, the first-of-its-kind RCT for acute intermediate-high risk pulmonary embolism (PE).

For patients with aortic stenosis, is earlier intervention beneficial? Mamas Mamas, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss.

Mamas Mamas and Gi-byoung Nam discuss edoxaban monotherapy in patients with high-risk AF and stable CAD.

Ajay Kirtane and C. Michael Gibson discuss how orbital atherectomy compares with balloon angioplasty for severely calcified coronary arteries before DES implantation.

Does long-term colchicine benefit patients after acute MI? C. Michael Gibson and Sanjit Jolly discuss.

Mamas Mamas talks to Jacob Thomsen Lønborg about how PCI affects outcomes for patients with stable CAD undergoing TAVI.

Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by referring specialists.

Johanne Silvain, Gilles Montalescot, and C. Michael Gibson discuss the effects of beta-blocker interruption in post-MI patients.

Patient selection is important for transcatheter interventions and impacts result success. This discussion focuses on defining what treatment goals should be, limitations of current interventions, and identifying appropriate transcatheter patients.

Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and Lp(a)—might be leveraged to reduce long-term risk. cf5fa450-73b2-11f0-b931-3b0dee8b3831

Clinical trials face challenges with variability in echo images, protocol adherence, and data quality. This discussion focuses on strategies to improve trial integrity, operational efficiency, and regulatory approval of transcatheter devices.

The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at NY Valves. This discussion provides a deeper dive into what this data means for the Intrepid mitral program and perspectives on the transcatheter landscape.

Renate Schnabel, Ruben Casado Arroyo, and Mamas Mamas discuss the atrial fibrillation recommendations unveiled at ESC Congress 2024.

Dipak Kotecha talks to C. Michael Gibson about whether educating healthcare providers on rhythm-control therapy affects guideline adherence and stroke outcomes.